Print   

Wednesday 03 December, 2008

Akers Biosciences

ABI Sells Tax Losses in State

RNS Number : 4228J
Akers Biosciences, Inc.
03 December 2008
 

Embargoed: 0700hrs3 December 2008


Akers Biosciences Inc.

('ABI' or the 'Company')


ABI Sells Tax Losses in State of New JerseyUSA


Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that is has sold certain historic tax losses, under an incentive program operated in the state of New Jersey, for a net cash sum of US$700,000.


New Jersey's 'Technology Business Tax Certificate Transfer Program' allows new and expanding technology companies to turn tax losses and credits into cash.  ABI was able to sell unused net operating losses to other corporate taxpayers in New Jersey at a discounted value and still retain the Federal tax losses to exploit, to its benefit, in the future.

Thomas A. Nicolette, Chief Executive Officer of ABI said,

'We are very pleased to benefit from the program operated by the state of New Jersey which has allowed ABI to add a further $700,000 to cash resources which currently stand at over US$5m. ABI is in an enviable position in that the Company is operationally profitable, debt free and has strong cash resources.'

Enquiries:


Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

    

Ben Simons
M: Communications
Tel. +44 (0)20 7153 1540


Alasdair Younie

Arbuthnot Securities Limited

Tel. +44 (0)20 7012 2000

 

About Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRZGMGZNZZGRZM

Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.



Investegate      © 2012 FE. All rights reserved.